Cocrystal Pharma, Inc. (COCP) stock: key figures, P/E, revenue and dividend
Health Care · United States · ISIN US19188J4094
Cocrystal Pharma, Inc. financials
| Fiscal year | 2025 |
|---|---|
| Operating income | -9.02 m USD |
| EBIT | -8.97 m USD |
| Net income | -8.83 m USD |
| Diluted EPS – continuing operations | -0.78 USD |
Full history since 2007, charts and your own formulas
This page shows the last two fiscal years. After free sign-up you get the full income statement, balance sheet and cash flow, price and dividend charts, your own formula metrics and a stock screener covering more than 8,000 companies.
About Cocrystal Pharma, Inc.
Cocrystal Pharma, Inc., a biotechnology company, focuses on the discovery and development of antiviral therapeutic treatments for serious and/or chronic viral diseases in the United States. The company employs structure-based technologies to create antiviral drugs including influenza virus, norovirus, coronaviruses, such as SARS-CoV-2 and MERS-CoV, as well as respiratory virus infections, and hepatitis C virus (HCV) infections. The company develops CC-42344, a novel PB2 inhibitor, which is in phase 2a clinical trial, as a potential treatment for pandemic and seasonal influenza A; and the inhaled CC-42344 for the potential prophylactic treatment of pandemic and seasonal influenza infections. It is also developing CDI-988, an oral pan-viral, which is a phase 1 clinical trial to treat noroviruses and coronaviruses, including SARS-CoV-2 and its variants; and CC-31244, an HCV non-nucleoside inhibitor that has completed Phase 2a clinical trial to treat HCV. The company has a license and research collaboration agreement with Merck Sharp & Dohme Corp. to discover and develop proprietary influenza A/B antiviral agents; and a license agreement with Kansas State University Research Foundation to develop antiviral compounds for the treatment of norovirus and coronavirus infections. Cocrystal Pharma, Inc. was headquartered in Bothell, Washington.
More stocks
- Pasithea Therapeutics Corp. (KTTA)
- NextPlat Corp (NXPL)
- Annovis Bio, Inc. (ANVS)
- Nexscient, Inc. (NXNT)
- Lipocine Inc. (LPCN)
- Motorsport Games Inc. (MSGM)
- Elauwit Connection, Inc. (ELWT)
- TANDY LEATHER FACTORY INC (TLF)
- Dominari Holdings Inc. (DOMH)
- Hawkeye Systems, Inc. (HWKE)
- SURGE COMPONENTS INC (SPRS)
- VEEA INC. (VEEA)
Not investment advice. All data without warranty, price as of 29.10.2026. Details in the risk notice.